Financial Analysis: Biocryst Pharmaceuticals Inc. (BCRX)’s Ratios Unveil Key Insights

Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

As of close of business last night, Biocryst Pharmaceuticals Inc.’s stock clocked out at $7.86, up 2.88% from its previous closing price of $7.64. In other words, the price has increased by $2.88 from its previous closing price. On the day, 1.52 million shares were traded. BCRX stock price reached its highest trading level at $7.86 during the session, while it also had its lowest trading level at $7.61.

Ratios:

To gain a deeper understanding of BCRX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.78 and its Current Ratio is at 2.82.

On September 18, 2023, RBC Capital Mkts Upgraded its rating to Outperform which previously was Sector Perform and also upped its target price recommendation from $9 to $10.

Jefferies Upgraded its Hold to Buy on August 04, 2023, while the target price for the stock was maintained at $11.

Insider Transactions:

Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jun 24 ’24 when McKee Amy E sold 8,600 shares for $6.32 per share. The transaction valued at 54,352 led to the insider holds 27,831 shares of the business.

SANDERS MACHELLE sold 4,689 shares of BCRX for $28,134 on Jun 17 ’24. The Director now owns 27,742 shares after completing the transaction at $6.00 per share. On Jun 14 ’24, another insider, HEGGIE THERESA, who serves as the Director of the company, sold 6,698 shares for $6.11 each. As a result, the insider received 40,925 and left with 52,852 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BCRX now has a Market Capitalization of 1626124032 and an Enterprise Value of 2204737536. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.25. Its current Enterprise Value per Revenue stands at 5.768 whereas that against EBITDA is -41.828.

Stock Price History:

Over the past 52 weeks, BCRX has reached a high of $8.09, while it has fallen to a 52-week low of $4.03. The 50-Day Moving Average of the stock is 13.17%, while the 200-Day Moving Average is calculated to be 33.53%.

Shares Statistics:

It appears that BCRX traded 3.14M shares on average per day over the past three months and 2271930 shares per day over the past ten days. A total of 205.77M shares are outstanding, with a floating share count of 195.56M. Insiders hold about 5.47% of the company’s shares, while institutions hold 82.04% stake in the company. Shares short for BCRX as of 1722384000 were 24384903 with a Short Ratio of 7.76, compared to 1719532800 on 17880493. Therefore, it implies a Short% of Shares Outstanding of 24384903 and a Short% of Float of 11.88.

Most Popular